Nonsteroidal Anti-Inflammatory Drugs: Cardiovascular, Cerebrovascular and Renal Effects

被引：64
作者：
Batlouni, Michel [1 ]
机构：
[1] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil
来源：
ARQUIVOS BRASILEIROS DE CARDIOLOGIA | 2010年 / 94卷 / 04期
关键词：
CYCLOOXYGENASE-2; SELECTIVITY; GASTROINTESTINAL TOXICITY; MYOCARDIAL-INFARCTION; CLINICAL-TRIAL; LATE-PHASE; RISK; INHIBITION; COX-2; METAANALYSIS; OSTEOARTHRITIS;
D O I：
10.1590/S0066-782X2010000400019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：556 / 563
页数：8
相关论文
共 40 条
[1]   Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident [J].
Abraham, N. S. ;
El-Serag, H. B. ;
Hartman, C. ;
Richardson, P. ;
Deswal, A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (08) :913-924
[2]   Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke - A nested case-control study [J].
Andersohn, Frank ;
Schade, Rene ;
Suissa, Samy ;
Garbe, Edeltraut .
STROKE, 2006, 37 (07) :1725-1730
[3]   Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].
Antman, Elliott M. ;
Bennett, Joel S. ;
Daugherty, Alan ;
Furberg, Curt ;
Roberts, Harold ;
Taubert, Kathryn A. .
CIRCULATION, 2007, 115 (12) :1634-1642
[4]   Cyclooxygenase inhibition and cardiovascular risk [J].
Antman, EM ;
DeMets, D ;
Loscalzo, J .
CIRCULATION, 2005, 112 (05) :759-770
[5]   ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].
Bhatt, Deepak L. ;
Scheiman, James ;
Abraham, Neena S. ;
Antman, Elliott M. ;
Chan, Francis K. L. ;
Furberg, Curt D. ;
Johnson, David A. ;
Mahaffey, Kenneth W. ;
Quigley, Eamonn M. .
CIRCULATION, 2008, 118 (18) :1894-1909
[6]   IBUPROFEN INDUCED HYPONATREMIA [J].
BLUM, M ;
AVIRAM, A .
RHEUMATOLOGY AND REHABILITATION, 1980, 19 (04) :258-259
[7]   Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning [J].
Bolli, R ;
Shinmura, K ;
Tang, XL ;
Kodani, E ;
Xuan, YT ;
Guo, YR ;
Dawn, B .
CARDIOVASCULAR RESEARCH, 2002, 55 (03) :506-519
[8]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[9]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[10]   Clinical trial design and patient demographics of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis [J].
Cannon, Christopher P. ;
Curtis, Sean P. ;
Bolognese, James A. ;
Laine, Loren .
AMERICAN HEART JOURNAL, 2006, 152 (02) :237-245
1234